Neotract said today a new analysis from the U.K.’s National Institute for Health and Care Excellence reported a (UK £286) $443 savings per patient per day when using its UroLift system to treat enlarged prostates, compared to the most common surgical intervention.
The NICE reported other benefits of the system, including preservation of sexual function, improved quality of life and reduced recovery time with the treatment, compared to the standard treatment, Pleasanton, Calif.-based Neotract said.
“The NICE report dovetails well with an analysis we published December 2013 in Population Health Management that showed an anticipated 30% savings of UroLift versus standard surgery, based on a two year horizon of care within the US Medicare system,” Jefferson College of Population Health Dr. David Nash said in a press release.
NeoTract said the Institute stated that the system “should be considered as an alternative to current surgical procedures for use in a day-case setting in men with lower urinary tract symptoms of benign prostatic hyperplasia who are aged 50 years and older and who have a prostate of less than 100 ml,” in the report.
The company said the U.K.’s National Health Service released “more appropriate” financial agreements for reimbursing use of the system to better “reflect the cost of care.”
“Both of these announcements independently, as well as the recent inclusion of UroLift into the European Association of Urology Guidelines, further support the clinical and economic value of this game-changing technology. We now expect that the tariff change coupled with this very supportive NICE advice will mean that most, if not all, UK hospitals can choose to offer UroLift in the near future,” CEO Dave Amerson said in prepared remarks.